DIRS.INFO The most relevant business & tech news

☆ Eli Lilly shares could be set for a big move if the Zepbound maker adds to its winning streak
▼ + stars: | 2024-10-29 | by ( Christina Cheddar Berk | In | ) www.cnbc.com time to read: +6 min

Revenue from obesity treatment Zepbound is forecast to climb to $1.73 billion from $1.24 billion quarter over quarter. For the year, analysts expect Mounjaro sales to reach $4.58 billion, while Zepbound revenue is seen rising to $5.88 billion. The consensus view for combined sales of both drugs now stands at $30.19 billion, according to FactSet. Other key announcements A clinical trial is in progress that pits Zepbound against Novo Nordisk's Wegovy in obesity treatment. Beyond obesity, Lilly has begun treating patients with Kisunla, its Alzheimer's disease treatment.

Persons: Eli Lilly, Lilly, Seamus Fernandez, Morgan Stanley, Terence Flynn, David Risinger, Morgan Stanley's Flynn, Mounjaro, Cantor, Louise Chen, —, Fred Imbert Organizations: Investment, Food, Leerink, Novo Nordisk's, FDA, Kisunla Locations: U.S

On a more positive note, Guggenheim upgraded GSK to buy thanks to strength across multiple product pipelines. Elsewhere, RBC upgraded Lyft to outperform, calling for a major rally ahead. Analyst Brad Erickson upgraded Lyft shares to outperform from sector perform, and raised his price target by $6 to $23, implying roughly 40.7% potential increase. — Pia Singh 6:10 a.m.: DoorDash upgraded by RBC on new partnerships potential, higher order growth RBC Capital Markets upgraded DoorDash to outperform from sector perform. Analyst Seamus Fernandez upgraded shares to buy from neutral and assigned a £20.31 price target, representing 21% upside to GSK's latest close.

Persons: Guggenheim, Wells Fargo, Timur Braziler, Braziler, — Pia Singh, Lyft, Brad Erickson, Erickson, Seamus Fernandez, Fernandez, Citi downgrades Ferrari, Ferrari, Harald Hendrikse, Fred Imbert Organizations: CNBC, Citi, Ferrari, GSK, RBC, Popular, RBC Capital Markets RBC Capital Markets, DASH, Capital Markets, Guggenheim Securities, drugmaker GSK, Guggenheim Locations: Wells Fargo, Puerto Rico, U.S, Wells, Shingrix, Arexvy, Milan

☆ This sector offers defensive and growth properties – along with some portfolio income
▼ + stars: | 2024-02-26 | by ( Darla Mercado | Cfp | ) www.cnbc.com time to read: +6 min

The health-care sector of the S & P 500 is up about 8% year to date, marking a sharp comeback from a largely flat 2023. Even as health care is making a comeback this year, investors shouldn't forget its defensive attributes. Back in 2022, when the S & P 500 fell 19.4%, the health-care sector slipped only 3.5% "When markets are challenged, health care can be a good place to be," Lyons added. Some of them speak to the growth aspects of health care and why you can play offense." Merger activity is another driver of growth in health care, as large pharmaceutical companies snap up nimble biotech firms that are at the forefront of developing treatments.

Persons: Dan Lyons, Janus Henderson, shouldn't, Lyons, ImmunoGen, Seamus Fernandez, Sotatercept, Cigna, Cantor Fitzgerald, Sarah James, Fred Imbert Organizations: Big Tech, . Healthcare, Janus, Janus Henderson Investors, U.S . Food, Drug Administration's Center, Drug, Research, FDA, Esai, Pharmaceuticals, CNBC Pro, Merck, Abbott Laboratories, AbbVie, CVS Health Locations: U.S

☆ Eli Lilly's Zepbound has a strong shot of being the biggest drug of all time: Guggenheim's Fernandez
▼ + stars: | 2023-11-08 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailEli Lilly's Zepbound has a strong shot of being the biggest drug of all time: Guggenheim's FernandezGuggenheim analyst Seamus Fernandez joins 'Power Lunch' to discuss Eli Lilly's latest drug to get FDA approval, whether it'll become the biggest-selling drug of all time, and who will be on the hook in paying for Eli Lilly's new drug.

Persons: Eli Lilly's Zepbound, Guggenheim's Fernandez Guggenheim, Seamus Fernandez, Eli, it'll, Eli Lilly's

☆ Wall Street hikes forecasts for anti-obesity drug sales to $100 billion and beyond — A look at the numbers
▼ + stars: | 2023-10-23 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +3 min

Most analysts predict the market for new weight loss drugs like Wegovy and Mounjaro will be enormous, but estimates vary for its exact size depending on who you ask. On Monday, Citi raised its estimate for incretin drug sales to $71 billion by 2035, up from its prior estimate of $55 billion. Last month, the firm made a case for there being a $150 billion to $200 billion opportunity for these drugs. At the moment, private insurance coverage isn't a guarantee for those seeking weight loss treatment, and the federal Medicare program doesn't cover weight loss drugs at all. Lilly expects the Food and Drug Administration to approve this drug to treat obesity by the end of this year.

Persons: Seamus, Fernandez, Andrew Baum, Goldman Sachs, Chris Shibutani, Shibutani, Eli Lilly, Lilly Organizations: Monday, Citi, Wegovy, Food and Drug Administration Locations: GLP

☆ AstraZeneca shares fall as lung cancer drug trial data abstract disappoints
▼ + stars: | 2023-10-18 | by ( ) www.reuters.com time to read: +2 min

REUTERS/Phil Noble/File Photo Acquire Licensing RightsOct 18 (Reuters) - Shares in AstraZeneca (AZN.L) fell more than 4% on Wednesday after a data abstract on its experimental precision drug's use in lung cancer patients in a late-stage trial disappointed some analysts. Fernandez added that progression-free survival in lung cancer patients came in below expectations. Barclays analyst Emily Field also said in a note that safety looked better than expected for lung cancer patients and the data abstracts were "collectively positive" for AstraZeneca. London-listed shares of AstraZeneca were down 3.7% at 1219 GMT, while the broader STOXX Health Care (.SXDP) index was off 1%. Shares of AstraZeneca's Japanese partner Daiichi Sankyo (4568.T), which is jointly developing the cancer drug, closed 4.6% lower on Tuesday.

Persons: Phil Noble, datopotamab deruxtecan, Jefferies, Stephen Barker, Barker, Seamus Fernandez, Fernandez, Emily Field, GSK's, Danilo Masoni, Maggie Fick, Bhanvi, Shinjini Organizations: AstraZeneca, REUTERS, European Society for Medical, Friday, Guggeinheim, Barclays, AstraZeneca ., Thomson Locations: Macclesfield, Britain, Madrid, AstraZeneca . London, U.S, Milan, London, Bengaluru

☆ Analysts predicted new obesity medicines would be blockbusters. Now they’re raising their forecasts
▼ + stars: | 2023-09-16 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

Fernandez sees a total addressable market of $140 billion to support patients with obesity. He expects there is a potential for GLP-1 drugs to become as common and widely used, much like statins are used to lower cholesterol. Morgan Stanley's Flynn estimates a 30% share of the diabetes market would generate $109 billion on a worldwide basis for GLP-1 drugs. Layer in a 15% to 30% share of the obesity market and that equates to worldwide sales of $97.4 billion to $194.8 billion. Guggenheim's estimates also assume that oral GLP-1 drugs that are currently in development are able to come to market a few years from now.

Persons: Seamus Fernandez, Fernandez, Lilly, Eli Lilly, Morgan Stanley, Terence Flynn, Eli Lilly's Mounjaro, Insulet, Canaccord, William Plovanic, Plovanic, It's, Morgan Stanley's Flynn, Flynn, Novo, Michael Bloom Organizations: Wall, Novo, American Heart Association, Food and Drug Administration, Novo Nordisk, Iqvia, Disease Control Locations: GLP

☆ How much is a good night's sleep worth? A lot to these stocks
▼ + stars: | 2023-09-04 | by ( Michelle Fox | ) www.cnbc.com time to read: +13 min

In fact, some 63% of U.S. adults sleep less than the recommended seven to nine hours a night, according to the National Sleep Foundation's Sleep Health Index. There are a myriad of products in the sleep arena — from mattresses and sleep supplements to sleep apnea devices and tech wearables that track sleep. Treating sleep conditions Health conditions can also impact the ability to get a good night's rest, like insomnia and sleep apnea. Obstructive sleep apnea causes breathing to be interrupted during sleep. About half of those surveyed in its obstructive sleep apnea patient survey in July said they had never heard of Inspire.

Persons: Anna Pione, they'll, Seth Basham, Basham, Tempur Sealy, " Basham, It's, Stefano Natella, Natella, it's, Ollie, Seamus Fernandez, Philip's, Philips, Eli Lilly, Eli Lilly's, Guggenheim's Fernandez, Michael Farrell, we've, Fernandez, Novo, wearables, Gene Munster, Jason Ware, Ware, Pione, Michael Bloom Organizations: McKinsey, International Sleep Products, Sealy International, Mattress, Sealy, Centers for Disease Control, Guggenheim, CDC, Unilever, American, of, Care, American Medical Association, Bank of America Securities, Medical Systems, Bank of America, Inspire, Novo Nordisk, Garmin, Apple, Deepwater Asset Management, Apple Watch, Albion Financial, Munster Locations: U.S, dreamland, Mizuho, Novo

☆ ASCO conference will put the focus on the fight against cancer. These stocks are in the spotlight
▼ + stars: | 2023-05-28 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +9 min

Developments in cancer research will be in the spotlight as the American Society of Clinical Oncology hosts the world's biggest cancer research conference in Chicago, starting Thursday. The pair has already has won regulatory approval for Enhertu for metastatic HER2-low breast cancer, but the companies are also studying its use in a variety other HER2 tumors in breast cancers. Lilly's drug, Verzenio, is used in high-risk patients with HR-positive HER2-negative breast cancer that is more likely to reoccur and has already breached the patient's lymph nodes. In a research note earlier this month, Guggenheim analyst Seamus Fernandez said Kisqali is already taking market share from Pfizer's Ibrance in metastatic breast cancer. Merck's Keytruda is also being watched for what benefits it could offer early-stage lung cancer patients .

Search resuls for: "Seamus Fernandez"

9 mentions found